October 10, 2024

Enfortumab Vedotin Plus Pembrolizumab Stands Strong as the Frontline Bladder Cancer SOC – OncLive

October 9, 2024

Study Uncovers Mutations and DNA Structures Driving Bladder Cancer – Weill Cornell Medicine Newsroom

October 8, 2024

Johnson & Johnson discontinues Phase III study of treatment for bladder cancer – Clinical Trials Arena

October 7, 2024

Variant Histology Bladder Cancer Challenges and Future Directions – Syed Hussain – UroToday

October 7, 2024

GREM1 may be a biological indicator and potential target of bladder cancer – Nature.com